You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Claims for Patent: 9,549,971

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,549,971

Title:	Methods for inhibiting angiogenesis using EGFL8 antagonists
Abstract:	The present invention provides methods of using EGFL8 antagonists to inhibit vascular development and to treat related disorders.
Inventor(s):	Ye; Weilan (Foster City, CA), Lu; Han (San Bruno, CA)
Assignee:	GENENTECH, INC. (South San Francisco, CA)
Application Number:	12/812,944
Patent Claims:	1. A method of reducing or inhibiting angiogenesis in a subject having a pathological condition associated with angiogenesis, comprising administering to the subject an EGFL8 antagonist, wherein EGFL8 has the sequence of SEQ ID NO:1 or SEQ ID NO:2, and wherein the EGFL8 antagonist is an anti-EGFL8 antibody or a fragment thereof which binds to EGFL8 and wherein the pathological condition is diabetic retinopathy, choroidal neovascularization (CVN), age-related macular degeneration (AMD), diabetic macular edema (DME), pathological myopia, von Hippel-Lindau disease, histoplasmosis of the eye, retinal vein occlusion (RVO), central retinal vein occlusion (CRVO), branched central retinal vein occlusion (BRVO), corneal neovascularization, retinal neovascularization, retinopathy of prematurity (ROP), subconjunctival hemorrhage, hypertensive retinonpathy, neovascular glaucoma or immune rejection of transplanted corneal tissue. 2. The method of claim 1, wherein the EGFL8 antagonist is an anti-EGFL8 antibody. 3. The method of claim 1, further comprising administering to the subject a second anti-angiogenic agent. 4. The method of claim 3, wherein the second anti-angiogenic agent is administered prior to or subsequent to the administration of the EGFL8 antagonist. 5. The method of claim 3, wherein the second anti-angiogenic agent is administered concurrently with the EGFL8 antagonist. 6. The method of claim 3, wherein the second anti-angiogenic agent is an anti-EGFL7 or an anti-vascular endothelial cell growth factor (VEGF) antibody. 7. The method of claim 6, wherein the anti-VEGF antibody is bevacizumab.

Details for Patent 9,549,971

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004	⤷ Try a Trial	2029-01-14
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.